DigitalPaladin

2 ms·

1. 1.▲
   by DigitalPaladin 10mo ago

   A relative of mine was in the late-stages of cancer, and was not able to find ANY trials willing to accept them. The worst of those trials was out of Baltimore (MD USA), and they ghosted my relative after initial in-person consults that re
2. 2.▲
   by DigitalPaladin 2y ago

   Anecdotally, I can support this. A loved one is moving through this pathway now. Its has you said: try all the established drugs first, even if they aren't directly indicated for the cancer diagnosis of the patient, then move on to th
3. 3.▲
   by DigitalPaladin 2y ago

   Are you referring to monoclonal antibodies? For which a Nobel Prize was awarded in 2018, and research has continued since the 80s?
4. 4.▲
   by DigitalPaladin 2y ago

   I'm assuming /s above. Because the amount of pencil-whipped "peer review" feedback I've received could fit in a shoe box, because many "reviewers" are looking for the CV credit for their role and not so mu
5. 5.▲
   by DigitalPaladin 2y ago

   Oh, yes. Repackaging and reframing of data - as mentioned in the OP article too - is a common practice for farming impact and article numbers too. Why do novel research when you can just partner up with your friends, bring your data and co
6. 6.▲
   by DigitalPaladin 2y ago

   I'm a recovering academic, and have not published since not long after defending my dissertation. I blame this behavior entirely on "publish or perish". The demands for novel, thoughtful and statistically-significant finding